Review – Kidney CancerVaccine Therapy in Patients with Renal Cell Carcinoma
Introduction
Renal cell carcinoma (RCC) accounts for 2–3% of all adult cancers. There is a general European annual increase in incidence of around 2%, except in Denmark and Sweden. Approximately 20–30% of patients present with metastatic disease [1]. Although surgery is the primary curative therapy for patients with localised RCC, the prognosis for patients with advanced metastatic disease is poor, with a 5-yr survival rate of <10% [2]. Until recently, the standard therapy for metastatic RCC (mRCC) has been cytokine-based immunotherapy with interleukin-2 (IL-2) and/or interferon alfa (IFN-α), with only few durable complete remissions. Therefore, new therapeutic agents with more effective antitumour activity are needed [3]. Recently, the antiangiogenic agents sunitinib, sorafenib, temsirolimus, and bevacizumab plus interferon were licensed in Europe for the treatment of mRCC [4].
Because RCC is one of the most immunoresponsive cancers in humans, immunotherapy remains a basis of promising treatment strategies. Nonspecific stimulations via cytokines, passive specific immunotherapy with antibodies, and active specific immunotherapy seem to be suitable options for RCC. The last category is the subject of this review.
The goal of developing curative RCC vaccines is to stimulate the immune system to recognise and to destroy existing tumour cells. RCC vaccines are explored in the metastatic and adjuvant setting. To date, they are only clinically effective in a minority of patients and are still considered experimental. This review provides an overview of the current knowledge of vaccine therapy for RCC and information on relevant clinical studies.
Section snippets
Evidence acquisition
A review was conducted of the recent literature regarding vaccine therapy for RCC. The following medical subject heading (MeSH) terms were identified in PubMed: Carcinoma, Renal Cell; Cancer Vaccines; Immunotherapy, Active; and Dendritic Cells. The search for the last three terms was performed by using the clinical queries using research methodology filters for the category therapy (based on the work of Haynes et al [5]). They were then linked with the option “OR” and combined with Carcinoma,
Evidence synthesis
The search retrieved 96 abstracts; 54 papers were relevant to use.
Conclusions
Despite the limited clinical efficacy of most of the therapeutic vaccines in RCC studies to date and their often small number of patients and nonstandardised methodology, there is still interest for the use of vaccines that have much less toxicity than other current therapies for RCC. One of the major obstacles for development of effective RCC vaccines has been the lack of TAAs. The discovery of new TAAs or immunostimulatory peptides and increasing insight in basic immunology and molecular
References (54)
- et al.
Renal cell carcinoma guideline
Eur Urol
(2007) - et al.
Therapeutic dendritic cell vaccination of patients with renal cell carcinoma
Eur Urol
(2006) - et al.
A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters
J Urol
(2000) - et al.
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial
Lancet
(2004) - et al.
Vaccines in renal cell carcinoma
Semin Oncol
(2006) - et al.
Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma
J Urol
(2002) - et al.
Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings
Mol Ther
(2004) - et al.
Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors: miscellaneous tumors
Ann Oncol
(2005) - et al.
Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells
J Urol
(1999) - et al.
Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma
Clin Immunol
(2007)
An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer
Eur J Cancer
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial
Lancet
Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches
J Cancer Res Clin Oncol
Renal cell carcinoma
Curr Opin Oncol
Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey
BMJ
Immunotherapy of renal cell carcinoma
Cancer Immunol Immunother
Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells
World J Urol
Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study
Cancer
Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma
Cancer Biother Radiopharm
Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma
Am J Clin Oncol
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer
Cancer Res
Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial
Hum Gene Ther
Allogeneic gene-modified tumour cells in metastatic kidney cancer. Report II
Folia Biol (Praha)
Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma
J Immunother
Translational mini-review series on vaccines: dendritic cell-based vaccines in renal cancer
Clin Exp Immunol
Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang
Clin Cancer Res
Cited by (66)
The current clinical landscape of personalized cancer vaccines
2022, Cancer Treatment ReviewsCitation Excerpt :The effectiveness of such autologous cell vaccines has been evaluated in several phase I and II clinical trials, including in advanced metastatic prostate [9], lung [10,11], colorectal [12], melanoma [13,14] and renal cell carcinoma (RCC) [15,16], and showed good safety profiles and therapeutic immune responses. For example, the autologous tumor cell lysate vaccine Reniale has demonstrated effectiveness in treating non-metastatic RCC [17]. When administered after nephrectomy, Reniale improved the 5-year progression-free-survival (PFS) of high-risk non-metastatic RCC patients at all tumor stages (77.4%) when compared to the control group (67.8%) [17,18].
Adenovirus vaccine therapy with CD137L promotes CD8<sup>+</sup> DCs-mediated multifunctional CD8<sup>+</sup> T cell immunity and elicits potent anti-tumor activity
2022, Pharmacological ResearchCitation Excerpt :Thus, the development of novel therapeutic strategies for patients with renal carcinoma is urgently needed. Vaccine therapy, as a powerful anti-tumor immunotherapy, triggers antigen-specific and persistent immune responses [6,7]. Notably, Adenovirus (Ad) are the most widely used vectors for gene delivery or vaccination owing to their high infection capacity and low toxicity, so Ad vaccines are emerging as promising candidates for cancer immunotherapy [8].
Perspectives and advancements in the design of nanomaterials for targeted cancer theranostics
2020, Chemico-Biological Interactions